Cutaneous T-cell lymphoma: molecular and cytogenetic findings.
Chromosomal changes have been identified early in the disease process in cutaneous T-cell lymphoma (CTCL): both losses and gains of chromatin have been found on several chromosomes. The extent of chromosomal aberrations increases with disease stage and in more aggressive subtypes of the disorder. Changes in specific genes, such as NAV3, have been characterized in patients with CTCL, and may produce a proliferation advantage for affected cells. In addition, the expression of some genes can discriminate between controls and patients with CTCL. Therefore, the over- or underexpression of certain genes may be of diagnostic and pathogenic relevance in this disease, and may allow the development of selective treatments.
Sterry
Wolfram
W
Department of Dermatology, and Allergy, Charité University Medicine, Berlin, Germany. wolfram.sterry@charite.de
D002869:Chromosome Aberrations; D002881:Chromosomes, Human, Pair 12; D019175:DNA Methylation; D016002:Discriminant Analysis; D015536:Down-Regulation; D017353:Gene Deletion; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D007621:Karyotyping; D016410:Lymphoma, T-Cell, Cutaneous / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008565:Membrane Proteins / Q000235:genetics; D009367:Neoplasm Staging; D009419:Nerve Tissue Proteins / Q000235:genetics; D012878:Skin Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D014178:Translocation, Genetic
D008565:Membrane Proteins; C464453:NAV3 protein, human; D009419:Nerve Tissue Proteins